Deep Track Capital LP Purchases New Stake in RAPT Therapeutics, Inc. (NASDAQ:RAPT)

Deep Track Capital LP bought a new stake in RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 6,011,380 shares of the company's stock, valued at approximately $9,498,000. Deep Track Capital LP owned about 17.20% of RAPT Therapeutics at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Bridgeway Capital Management LLC boosted its stake in RAPT Therapeutics by 66.7% during the 4th quarter. Bridgeway Capital Management LLC now owns 125,000 shares of the company's stock worth $198,000 after purchasing an additional 50,000 shares during the period. BVF Inc. IL acquired a new stake in shares of RAPT Therapeutics in the fourth quarter valued at about $14,595,000. Comerica Bank purchased a new position in RAPT Therapeutics during the 4th quarter valued at about $92,000. TCG Crossover Management LLC purchased a new position in RAPT Therapeutics during the 4th quarter valued at about $19,751,000. Finally, Nantahala Capital Management LLC purchased a new position in RAPT Therapeutics during the 4th quarter valued at about $1,965,000. 99.09% of the stock is owned by hedge funds and other institutional investors.

RAPT Therapeutics Stock Performance

RAPT Therapeutics stock traded up $0.09 during trading on Monday, reaching $0.84. The company had a trading volume of 437,069 shares, compared to its average volume of 1,262,156. RAPT Therapeutics, Inc. has a 12-month low of $0.75 and a 12-month high of $4.83. The stock's 50 day moving average price is $1.03 and its two-hundred day moving average price is $1.25. The firm has a market capitalization of $111.28 million, a price-to-earnings ratio of -0.30 and a beta of -0.04.

RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.23. As a group, research analysts expect that RAPT Therapeutics, Inc. will post -2.14 earnings per share for the current year.

Analyst Ratings Changes

Separately, HC Wainwright restated a "buy" rating and set a $10.00 target price on shares of RAPT Therapeutics in a report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $4.00.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.